RXRX - RECURSION PHARMACEUTICALS, INC.
3.54
-0.100 -2.825%
Share volume: 13,962,391
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$3.64
-0.10
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-06-2024 | 02-28-2025 | 05-05-2025 | 11-05-2025 | 02-25-2026 | |
| Assets | ||||||||
| Total Assets | 557.847 M | 775.861 M | 726.499 M | 1.449 B | 1.305 B | 1.400 B | 1.474 B | |
| Current Assets | 343.615 M | 522.375 M | 474.172 M | 714.269 M | 584.145 M | 714.105 M | 812.845 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 41.495 M | 43.725 M | 42.715 M | 67.708 M | 32.023 M | 29.223 M | 28.566 M | |
| Short Term Investments | 41.495 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 2.599 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 296.326 M | 474.341 M | 427.647 M | 594.350 M | 500.453 M | 659.836 M | 743.294 M | |
| Total Non-current Assets | 214.232 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 86.716 M | 83.633 M | 84.410 M | 141.063 M | 126.834 M | 111.706 M | 103.931 M | |
| Other Assets | 35.755 M | 169.853 M | 167.917 M | 593.266 M | 594.255 M | 573.715 M | 557.354 M | |
| Intangible Assets | 33.076 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 52.056 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 557.847 M | 775.861 M | 726.499 M | 1.449 B | 1.305 B | 1.400 B | 1.474 B | |
| Total liabilities | 156.696 M | 191.412 M | 201.940 M | 413.816 M | 371.287 M | 352.578 M | 343.265 M | |
| Total current liabilities | 73.920 M | 86.083 M | 108.888 M | 187.472 M | 141.981 M | 155.103 M | 147.707 M | |
| Accounts Payable | 5.115 M | 3.762 M | 2.260 M | 21.613 M | 25.086 M | 13.935 M | 18.118 M | |
| Other liabilities | 37.391 M | 53.239 M | 56.662 M | 71.982 M | 60.814 M | 51.057 M | 48.727 M | |
| Current long term debt | 6.117 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 44.857 M | 22.921 M | 20.510 M | 19.022 M | 16.446 M | 11.902 M | 9.564 M | |
| Other liabilities | 37.391 M | 53.239 M | 56.662 M | 71.982 M | 60.814 M | 51.057 M | 48.727 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 401.151 M | 584.449 M | 524.559 M | 1.035 B | 933.947 M | 1.047 B | 1.131 B | |
| Common stock | 236.019 M | 1.741 B | 1.777 B | 2.474 B | 2.553 B | 2.981 B | 3.170 B | |
| Retained earnings | -1.059 B | -1.157 B | -1.252 B | -1.431 B | -1.634 B | -1.968 B | -2.076 B |